Cargando…
IQP-GC-101 Reduces Body Weight and Body Fat Mass: A Randomized, Double-Blind, Placebo-Controlled Study
IQP-GC-101 is a patented blend of the standardized extracts of Garcinia cambogia, Camellia sinensis, unroasted Coffea arabica, and Lagerstroemia speciosa. These individual ingredients of IQP-GC-101 have each shown promise in promoting weight loss; however, the efficacy of the blend has not been esta...
Autores principales: | Chong, Pee-Win, Beah, Zhi-Ming, Grube, Barbara, Riede, Linda |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4235473/ https://www.ncbi.nlm.nih.gov/pubmed/24797657 http://dx.doi.org/10.1002/ptr.5158 |
Ejemplares similares
-
Weight Maintenance with Litramine (IQP-G-002AS): A 24-Week Double-Blind, Randomized, Placebo-Controlled Study
por: Grube, Barbara, et al.
Publicado: (2015) -
Sleep Promoting Effects of IQP-AO-101: A Double-Blind, Randomized, Placebo-Controlled Exploratory Trial
por: Bongartz, Udo, et al.
Publicado: (2019) -
Evaluation of Benefit and Tolerability of IQP‐CL‐101 (Xanthofen) in the Symptomatic Improvement of Irritable Bowel Syndrome: A Double‐Blinded, Randomised, Placebo‐Controlled Clinical Trial
por: Alt, Felix, et al.
Publicado: (2017) -
Microbiota Composition and Diversity in Weight Loss Population After the Intake of IQP-AE-103 in a Double-Blind, Randomized, Placebo-Controlled Study
por: Peng, Li Vern, et al.
Publicado: (2022) -
Double-Blind, Randomized, Three-Armed, Placebo-Controlled, Clinical Investigation to Evaluate the Benefit and Tolerability of Two Dosages of IQP-AE-103 in Reducing Body Weight in Overweight and Moderately Obese Subjects
por: Uebelhack, Ralf, et al.
Publicado: (2019)